 | • レポートコード：GIR-2104Z09101 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、髄膜炎菌性疾患治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。髄膜炎菌性疾患治療薬の種類別市場規模（注射剤、経口）、用途別市場規模（病院、ドラッグストア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・髄膜炎菌性疾患治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、GlaxoSmithKline、Sanofi Pasteur、Novartis ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：注射剤、経口 ・用途別分析2016年-2026年：病院、ドラッグストア、その他 ・髄膜炎菌性疾患治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・髄膜炎菌性疾患治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・髄膜炎菌性疾患治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・髄膜炎菌性疾患治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・髄膜炎菌性疾患治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Meningococcal Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Meningococcal Disease Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Meningococcal Disease Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Meningococcal Disease Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Injectable
Oral
Market segment by Application can be divided into
Hospitals
Drugstores
Others
The key market players for global Meningococcal Disease Drugs market are listed below:
Pfizer
GlaxoSmithKline
Sanofi Pasteur
Novartis
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Meningococcal Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Meningococcal Disease Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Injectable
1.2.3 Oral
1.3 Market Analysis by Application
1.3.1 Overview: Global Meningococcal Disease Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Meningococcal Disease Drugs Market Size & Forecast
1.4.1 Global Meningococcal Disease Drugs Sales in Value (2016-2026))
1.4.2 Global Meningococcal Disease Drugs Sales in Volume (2016-2026)
1.4.3 Global Meningococcal Disease Drugs Price by Type (2016-2026) & (USD/MT)
1.5 Global Meningococcal Disease Drugs Production Capacity Analysis
1.5.1 Global Meningococcal Disease Drugs Total Production Capacity (2016-2026)
1.5.2 Global Meningococcal Disease Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Meningococcal Disease Drugs Market Drivers
1.6.2 Meningococcal Disease Drugs Market Restraints
1.6.3 Meningococcal Disease Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Meningococcal Disease Drugs Product and Services
2.1.4 Pfizer Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Meningococcal Disease Drugs Product and Services
2.2.4 GlaxoSmithKline Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Sanofi Pasteur
2.3.1 Sanofi Pasteur Details
2.3.2 Sanofi Pasteur Major Business
2.3.3 Sanofi Pasteur Meningococcal Disease Drugs Product and Services
2.3.4 Sanofi Pasteur Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Meningococcal Disease Drugs Product and Services
2.4.4 Novartis Meningococcal Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Meningococcal Disease Drugs Sales by Manufacturer
3.1 Global Meningococcal Disease Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Meningococcal Disease Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Meningococcal Disease Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Meningococcal Disease Drugs Manufacturer Market Share
3.4.2 Top 6 Meningococcal Disease Drugs Manufacturer Market Share
3.5 Global Meningococcal Disease Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Meningococcal Disease Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Meningococcal Disease Drugs Market Size by Region
4.1.1 Global Meningococcal Disease Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Meningococcal Disease Drugs Revenue by Region (2016-2026)
4.2 North America Meningococcal Disease Drugs Revenue (2016-2026)
4.3 Europe Meningococcal Disease Drugs Revenue (2016-2026)
4.4 Asia-Pacific Meningococcal Disease Drugs Revenue (2016-2026)
4.5 South America Meningococcal Disease Drugs Revenue (2016-2026)
4.6 Middle East and Africa Meningococcal Disease Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Meningococcal Disease Drugs Sales in Volume by Type (2016-2026)
5.2 Global Meningococcal Disease Drugs Revenue by Type (2016-2026)
5.3 Global Meningococcal Disease Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Meningococcal Disease Drugs Sales in Volume by Application (2016-2026)
6.2 Global Meningococcal Disease Drugs Revenue by Application (2016-2026)
6.3 Global Meningococcal Disease Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Meningococcal Disease Drugs Sales by Type (2016-2026)
7.2 North America Meningococcal Disease Drugs Sales by Application (2016-2026)
7.3 North America Meningococcal Disease Drugs Market Size by Country
7.3.1 North America Meningococcal Disease Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Meningococcal Disease Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Meningococcal Disease Drugs Sales by Type (2016-2026)
8.2 Europe Meningococcal Disease Drugs Sales by Application (2016-2026)
8.3 Europe Meningococcal Disease Drugs Market Size by Country
8.3.1 Europe Meningococcal Disease Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Meningococcal Disease Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Meningococcal Disease Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Meningococcal Disease Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Meningococcal Disease Drugs Market Size by Region
9.3.1 Asia-Pacific Meningococcal Disease Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Meningococcal Disease Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Meningococcal Disease Drugs Sales by Type (2016-2026)
10.2 South America Meningococcal Disease Drugs Sales by Application (2016-2026)
10.3 South America Meningococcal Disease Drugs Market Size by Country
10.3.1 South America Meningococcal Disease Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Meningococcal Disease Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Meningococcal Disease Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Meningococcal Disease Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Meningococcal Disease Drugs Market Size by Country
11.3.1 Middle East & Africa Meningococcal Disease Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Meningococcal Disease Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Meningococcal Disease Drugs Typical Distributors
12.3 Meningococcal Disease Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Meningococcal Disease Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Meningococcal Disease Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Meningococcal Disease Drugs Product and Services
Table 6. Pfizer Meningococcal Disease Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Meningococcal Disease Drugs Product and Services
Table 10. GlaxoSmithKline Meningococcal Disease Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 12. Sanofi Pasteur Major Business
Table 13. Sanofi Pasteur Meningococcal Disease Drugs Product and Services
Table 14. Sanofi Pasteur Meningococcal Disease Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novartis Basic Information, Manufacturing Base and Competitors
Table 16. Novartis Major Business
Table 17. Novartis Meningococcal Disease Drugs Product and Services
Table 18. Novartis Meningococcal Disease Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Global Meningococcal Disease Drugs Sales by Manufacturer (2019-2021e) & (K MT)
Table 20. Global Meningococcal Disease Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 21. Market Position of Manufacturers in Meningococcal Disease Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 22. Global Meningococcal Disease Drugs Production Capacity by Company, (K MT): 2020 VS 2021
Table 23. Head Office and Meningococcal Disease Drugs Production Site of Key Manufacturer
Table 24. Global Meningococcal Disease Drugs Sales by Region (2016-2021e) & (K MT)
Table 25. Global Meningococcal Disease Drugs Sales by Region (2021-2026) & (K MT)
Table 26. Global Meningococcal Disease Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 27. Global Meningococcal Disease Drugs Revenue by Region (2021-2026) & (USD Million)
Table 28. Global Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 29. Global Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 30. Global Meningococcal Disease Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 31. Global Meningococcal Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 32. Global Meningococcal Disease Drugs Price by Type (2016-2021e) & (USD/MT)
Table 33. Global Meningococcal Disease Drugs Price by Type (2021-2026) & (USD/MT)
Table 34. Global Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 35. Global Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 36. Global Meningococcal Disease Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 37. Global Meningococcal Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 38. Global Meningococcal Disease Drugs Price by Application (2016-2021e) & (USD/MT)
Table 39. Global Meningococcal Disease Drugs Price by Application (2021-2026) & (USD/MT)
Table 40. North America Meningococcal Disease Drugs Sales by Country (2016-2021e) & (K MT)
Table 41. North America Meningococcal Disease Drugs Sales by Country (2021-2026) & (K MT)
Table 42. North America Meningococcal Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 43. North America Meningococcal Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 44. North America Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 45. North America Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 46. North America Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 47. North America Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 48. Europe Meningococcal Disease Drugs Sales by Country (2016-2021e) & (K MT)
Table 49. Europe Meningococcal Disease Drugs Sales by Country (2021-2026) & (K MT)
Table 50. Europe Meningococcal Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 51. Europe Meningococcal Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 52. Europe Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 53. Europe Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 54. Europe Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 55. Europe Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 56. Asia-Pacific Meningococcal Disease Drugs Sales by Region (2016-2021e) & (K MT)
Table 57. Asia-Pacific Meningococcal Disease Drugs Sales by Region (2021-2026) & (K MT)
Table 58. Asia-Pacific Meningococcal Disease Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 59. Asia-Pacific Meningococcal Disease Drugs Revenue by Region (2021-2026) & (USD Million)
Table 60. Asia-Pacific Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 61. Asia-Pacific Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 62. Asia-Pacific Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 63. Asia-Pacific Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 64. South America Meningococcal Disease Drugs Sales by Country (2016-2021e) & (K MT)
Table 65. South America Meningococcal Disease Drugs Sales by Country (2021-2026) & (K MT)
Table 66. South America Meningococcal Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 67. South America Meningococcal Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 68. South America Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 69. South America Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 70. South America Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 71. South America Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 72. Middle East & Africa Meningococcal Disease Drugs Sales by Country (2016-2021e) & (K MT)
Table 73. Middle East & Africa Meningococcal Disease Drugs Sales by Country (2021-2026) & (K MT)
Table 74. Middle East & Africa Meningococcal Disease Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 75. Middle East & Africa Meningococcal Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 76. Middle East & Africa Meningococcal Disease Drugs Sales by Type (2016-2021e) & (K MT)
Table 77. Middle East & Africa Meningococcal Disease Drugs Sales by Type (2021-2026) & (K MT)
Table 78. Middle East & Africa Meningococcal Disease Drugs Sales by Application (2016-2021e) & (K MT)
Table 79. Middle East & Africa Meningococcal Disease Drugs Sales by Application (2021-2026) & (K MT)
Table 80. Direct Channel Pros & Cons
Table 81. Indirect Channel Pros & Cons
Table 82. Meningococcal Disease Drugs Typical Distributors
Table 83. Meningococcal Disease Drugs Typical Customers
List of Figures
Figure 1. Meningococcal Disease Drugs Picture
Figure 2. Global Meningococcal Disease Drugs Sales Market Share by Type in 2020
Figure 3. Injectable
Figure 4. Oral
Figure 5. Global Meningococcal Disease Drugs Sales Market Share by Application in 2020
Figure 6. Hospitals
Figure 7. Drugstores
Figure 8. Others
Figure 9. Global Meningococcal Disease Drugs Market Size, (USD Million) & (K MT): 2020 VS 2021 VS 2026
Figure 10. Global Meningococcal Disease Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. United States Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 12. Canada Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Mexico Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Germany Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. France Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. United Kingdom Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Russia Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Italy Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. China Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Japan Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Korea Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. India Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Southeast Asia Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Australia Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Brazil Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Egypt Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Saudi Arabia Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. South Africa Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Turkey Meningococcal Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Global Meningococcal Disease Drugs Sales (2016-2026) & (K MT)
Figure 31. Global Meningococcal Disease Drugs Production Capacity (2016-2026) & (K MT)
Figure 32. Global Meningococcal Disease Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 33. Meningococcal Disease Drugs Market Drivers
Figure 34. Meningococcal Disease Drugs Market Restraints
Figure 35. Meningococcal Disease Drugs Market Trends
Figure 36. Global Meningococcal Disease Drugs Sales Market Share by Manufacturer in 2020
Figure 37. Global Meningococcal Disease Drugs Revenue Market Share by Manufacturer in 2020
Figure 38. Meningococcal Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 39. Top 3 Meningococcal Disease Drugs Manufacturer (Revenue) Market Share in 2020
Figure 40. Top 6 Meningococcal Disease Drugs Manufacturer (Revenue) Market Share in 2020
Figure 41. Global Meningococcal Disease Drugs Sales Market Share by Region (2016-2026)
Figure 42. Global Meningococcal Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 43. North America Meningococcal Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 44. Europe Meningococcal Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Meningococcal Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 46. South America Meningococcal Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 47. Middle East & Africa Meningococcal Disease Drugs Revenue (2016-2026) & (USD Million)
Figure 48. Global Meningococcal Disease Drugs Sales Market Share by Type (2016-2026)
Figure 49. Global Meningococcal Disease Drugs Revenue Market Share by Type (2016-2026)
Figure 50. Global Meningococcal Disease Drugs Price by Type (2016-2026) & (USD/MT)
Figure 51. Global Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 52. Global Meningococcal Disease Drugs Revenue Market Share by Application (2016-2026)
Figure 53. Global Meningococcal Disease Drugs Price by Application (2016-2026) & (USD/MT)
Figure 54. North America Meningococcal Disease Drugs Sales Market Share by Country (2016-2026)
Figure 55. North America Meningococcal Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 56. North America Meningococcal Disease Drugs Sales Market Share by Type (2016-2026)
Figure 57. North America Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 58. Europe Meningococcal Disease Drugs Sales Market Share by Country (2016-2026)
Figure 59. Europe Meningococcal Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 60. Europe Meningococcal Disease Drugs Sales Market Share by Type (2016-2026)
Figure 61. Europe Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Meningococcal Disease Drugs Sales Market Share by Region (2016-2026)
Figure 63. Asia-Pacific Meningococcal Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Meningococcal Disease Drugs Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 66. South America Meningococcal Disease Drugs Sales Market Share by Country (2016-2026)
Figure 67. South America Meningococcal Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 68. South America Meningococcal Disease Drugs Sales Market Share by Type (2016-2026)
Figure 69. South America Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Meningococcal Disease Drugs Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Meningococcal Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Meningococcal Disease Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Meningococcal Disease Drugs Sales Market Share by Application (2016-2026)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の髄膜炎菌性疾患治療市場規模・現状・予測（2021年-2027年） Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant …- 世界の髄膜炎菌性疾患治療市場 2021：企業別、地域別、種類・用途別 The Meningococcal Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
- 世界の菌結合型髄膜炎市場規模・現状・予測（2021年-2027年） Meningococcal disease can become life threatening quickly, and teens are at higher risk of getting it. It's a leading cause of bacterial meningitis in teens. Meningitis is a dangerous inflammation of the lining of the brain and spinal cord. Two meningitis vaccines protects against four types of meni…
- 世界のクラッベ病治療薬市場規模・現状・予測（2021年-2027年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 世界のメニエール病治療薬市場規模・現状・予測（2021年-2027年） Meniere’s disease is a disorder of middle ear that causes vertigo, ringing sound in the ear and hearing problems. In most of the cases this disease only affects one ear. Meniere’s disease can affect anyone but the prevalence is on a higher side in people aged from 20-50. This is a chronic disease bu…